Cargando…
When Autoimmunity ‘DRESSes up’: A Case after Certolizumab Therapy
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is characterised by skin rash together with visceral organ involvement, lymphadenopathy, eosinophilia and atypical lymphocytosis. The syndrome is clinically heterogeneous, making diagnosis challenging. It has an annual incidence of 2 per...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SMC Media Srl
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426962/ https://www.ncbi.nlm.nih.gov/pubmed/36051169 http://dx.doi.org/10.12890/2022_003451 |
_version_ | 1784778796845498368 |
---|---|
author | Marigliano, Benedetta Rosa, Federico Internullo, Mattia Scuro, Luigi Tavanti, Andrea Del Vecchio, Lucia Rita Romagno, Francesco Paolo Schito, Maria Barbara Pace, Federica Colombo, Giovanni Maria Guglielmelli, Emanuele |
author_facet | Marigliano, Benedetta Rosa, Federico Internullo, Mattia Scuro, Luigi Tavanti, Andrea Del Vecchio, Lucia Rita Romagno, Francesco Paolo Schito, Maria Barbara Pace, Federica Colombo, Giovanni Maria Guglielmelli, Emanuele |
author_sort | Marigliano, Benedetta |
collection | PubMed |
description | Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is characterised by skin rash together with visceral organ involvement, lymphadenopathy, eosinophilia and atypical lymphocytosis. The syndrome is clinically heterogeneous, making diagnosis challenging. It has an annual incidence of 2 per 100,000 population and a mortality rate of 2–10%. We describe the first case of DRESS induced by certolizumab, a biologic disease-modifying antirheumatic drug (bioDMARD). LEARNING POINTS: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is an uncommon and under-reported syndrome. Its recognition is critical for treatment, especially in the emergency setting where most patients first present. In the case of unexplained fever, lymphadenopathy, cutaneous rash and characteristic laboratory findings (e.g., eosinophilia), after infectious causes have been ruled out, clinicians should always keep DRESS in mind and consider possible recent intake of a triggering drug. |
format | Online Article Text |
id | pubmed-9426962 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SMC Media Srl |
record_format | MEDLINE/PubMed |
spelling | pubmed-94269622022-08-31 When Autoimmunity ‘DRESSes up’: A Case after Certolizumab Therapy Marigliano, Benedetta Rosa, Federico Internullo, Mattia Scuro, Luigi Tavanti, Andrea Del Vecchio, Lucia Rita Romagno, Francesco Paolo Schito, Maria Barbara Pace, Federica Colombo, Giovanni Maria Guglielmelli, Emanuele Eur J Case Rep Intern Med Articles Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is characterised by skin rash together with visceral organ involvement, lymphadenopathy, eosinophilia and atypical lymphocytosis. The syndrome is clinically heterogeneous, making diagnosis challenging. It has an annual incidence of 2 per 100,000 population and a mortality rate of 2–10%. We describe the first case of DRESS induced by certolizumab, a biologic disease-modifying antirheumatic drug (bioDMARD). LEARNING POINTS: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is an uncommon and under-reported syndrome. Its recognition is critical for treatment, especially in the emergency setting where most patients first present. In the case of unexplained fever, lymphadenopathy, cutaneous rash and characteristic laboratory findings (e.g., eosinophilia), after infectious causes have been ruled out, clinicians should always keep DRESS in mind and consider possible recent intake of a triggering drug. SMC Media Srl 2022-07-14 /pmc/articles/PMC9426962/ /pubmed/36051169 http://dx.doi.org/10.12890/2022_003451 Text en © EFIM 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under a Commons Attribution Non-Commercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | Articles Marigliano, Benedetta Rosa, Federico Internullo, Mattia Scuro, Luigi Tavanti, Andrea Del Vecchio, Lucia Rita Romagno, Francesco Paolo Schito, Maria Barbara Pace, Federica Colombo, Giovanni Maria Guglielmelli, Emanuele When Autoimmunity ‘DRESSes up’: A Case after Certolizumab Therapy |
title | When Autoimmunity ‘DRESSes up’: A Case after Certolizumab Therapy |
title_full | When Autoimmunity ‘DRESSes up’: A Case after Certolizumab Therapy |
title_fullStr | When Autoimmunity ‘DRESSes up’: A Case after Certolizumab Therapy |
title_full_unstemmed | When Autoimmunity ‘DRESSes up’: A Case after Certolizumab Therapy |
title_short | When Autoimmunity ‘DRESSes up’: A Case after Certolizumab Therapy |
title_sort | when autoimmunity ‘dresses up’: a case after certolizumab therapy |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426962/ https://www.ncbi.nlm.nih.gov/pubmed/36051169 http://dx.doi.org/10.12890/2022_003451 |
work_keys_str_mv | AT mariglianobenedetta whenautoimmunitydressesupacaseaftercertolizumabtherapy AT rosafederico whenautoimmunitydressesupacaseaftercertolizumabtherapy AT internullomattia whenautoimmunitydressesupacaseaftercertolizumabtherapy AT scuroluigi whenautoimmunitydressesupacaseaftercertolizumabtherapy AT tavantiandrea whenautoimmunitydressesupacaseaftercertolizumabtherapy AT delvecchioluciarita whenautoimmunitydressesupacaseaftercertolizumabtherapy AT romagnofrancescopaolo whenautoimmunitydressesupacaseaftercertolizumabtherapy AT schitomariabarbara whenautoimmunitydressesupacaseaftercertolizumabtherapy AT pacefederica whenautoimmunitydressesupacaseaftercertolizumabtherapy AT colombogiovannimaria whenautoimmunitydressesupacaseaftercertolizumabtherapy AT guglielmelliemanuele whenautoimmunitydressesupacaseaftercertolizumabtherapy |